Month: June 2026

Introduction and Objective: Teplizumab (TPZ), an anti-CD3 monoclonal antibody, is approved in the US to delay stage 3 T1D onset in individuals aged ≥8 years (y) with stage 2 T1D. We present screening and real-world treatment (Tx) patterns from individuals in the US who received TPZ according to their age group.Methods: TEPLI-REAL (NCT06892002) was a […]

Introduction and Objective: Insulin-like growth factor-1 receptor (IGF-1R) inhibitor has been developed as an effective therapy for thyroid eye disease (TED). However, treatment-associated hyperglycemia remains a clinical concern. We aimed to examine whether early glycemic deterioration during IGF-1R inhibitor therapy is associated with subsequent glycemic trajectories and to develop and validate a risk prediction model.Methods: […]

Introduction and Objective: The Diabetes Prevention Program’s (DPP) standardized goal of ≥150 mins of physical activity (PA)/week leads to long-term health benefits. We examined the association between virtual DPP PA goal attainment and three distinct program engagement components: session completion, self-monitoring, and social interactions.Methods: We included women Veterans participating in virtual DPP across 11 VA […]

Introduction and Objective: Pancreatic islets maintain glucose homeostasis, with diabetes mellitus arising from autoimmune destruction (T1D) or dysregulation (T2D) of insulin-producing pancreatic β-cells. While exogenous insulin treats T1D, transplanted stem cell-derived islet-like cells may offer improved glycemic control with fewer long-term complications. However, a better understanding of pancreas and islet development is needed for successfully […]

Introduction and Objective: Although obesity is a major driver of type 2 diabetes (T2D), lean T2D represents 3-8% of global cases and remains understudied. Diabetes-associated cardiovascular disease is well characterized; vascular modeling of lean T2D is limited. We aim to determine whether induced pluripotent stem cell (iPSC)-derived endothelial cells from patients with lean T2D exhibit […]

Introduction and Objective: Despite GLP1ra or SGLT2i therapy, many adults with insulin treated type 2 diabetes (T2D) remain above HbA1c targets. AID may provide benefit for T2D. The study objective was to evaluate efficacy and safety of the twiist AID system, which uses the novel twiist pump and Tidepool Loop algorithm, in adults with insulin-treated […]

Introduction and Objective: Virtual environments may enhance social support through interactive and immersive engagement; however, evidence of their long-term impact remains limited. This study aims to examine the effect of a 3D virtual diabetes self-management education and support (DSME/S) intervention (Learning in a Virtual Environment [LIVE]) on perceived social support and its association with behavioral […]

Introduction and Objective: Type 1 diabetes (T1D) leads to vascular complications including chronic kidney disease (CKD) and major adverse cardiovascular events (MACE). Patients with T1D are at high risk for developing CKD, but contemporary data on the natural history of kidney function decline and the effect of therapies on slowing eGFR decline in T1D-related CKD […]

Introduction and Objective: Hypercortisolism is present in almost 1 in 4 patients with difficult-to-control type 2 diabetes (T2D) per the CATALYST study, yet often goes undetected as current diagnostics rely on single-timepoint assessments. These patients undergo escalation of medication for glycemic control without assessing underlying metabolic contributors. Continuous cortisol monitoring (CCM), analogous to continuous glucose […]

Introduction and Objective: While high-dose metformin use often signals advanced disease, the clinical relevance of dose-associated proteomic profile remains unclear. We aimed to identify a dose-dependent proteomic profile and associations with clinical traits and cardiometabolic events.Methods: In a discovery cohort of 1,246 Koreans with type 2 diabetes and eGFR >30 mL/min/1.73 m², we analyzed 5,416 […]